Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H I Saba

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Blood|April 1, 1994
High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myelomaO F Ballester, L C Moscinski, G H Lyman, et al.
American Journal of Hematology|March 1, 1989
Spontaneous platelet aggregation in type IIB Tampa von Willebrand disease is inhibited by the 52/48-kDa fragment of normal von Willebrand factor, which contains the GPIb binding domainH I Saba, Y Fujimura, S R Saba, et al.
Rheumatology International|January 1, 1982
In vitro cytotoxicity of human endothelial cells in polymyalgia rheumatica and giant cell arteritisT S Bocanegra, B F Germain, H I Saba, et al.
British Journal of Haematology|March 1, 1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myelomaO F Ballester, L C Moscinski, K K Fields, et al.
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Acute Myelogenous LeukemiaF R Appelbaum, M R Baer, M H Carabasi, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Chronic Myelogenous LeukemiaE Berman, R A Clift, E A Copelan, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Blood|April 1, 1994
High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myelomaO F Ballester, L C Moscinski, G H Lyman, et al.
American Journal of Hematology|March 1, 1989
Spontaneous platelet aggregation in type IIB Tampa von Willebrand disease is inhibited by the 52/48-kDa fragment of normal von Willebrand factor, which contains the GPIb binding domainH I Saba, Y Fujimura, S R Saba, et al.
Rheumatology International|January 1, 1982
In vitro cytotoxicity of human endothelial cells in polymyalgia rheumatica and giant cell arteritisT S Bocanegra, B F Germain, H I Saba, et al.
British Journal of Haematology|March 1, 1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myelomaO F Ballester, L C Moscinski, K K Fields, et al.
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Acute Myelogenous LeukemiaF R Appelbaum, M R Baer, M H Carabasi, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Chronic Myelogenous LeukemiaE Berman, R A Clift, E A Copelan, et al.
Pageof 5